Study questions certain breast cancer treatment

November 09, 2017 04:54 AM

Patients with estrogen receptor positive breast cancer typically are treated with either tamoxifen or aromatase inhibitors for five years after their cancer treatment finishes.

But a new study suggests that may not be long enough. Researchers at the University of Michigan looked at women with ER positive breast cancer. They found those who originally had large tumors had up to a 40 percent chance of a recurrence 20 years later.

Advertisement – Content Continues Below

Experts say it could indicate patients might need to stay on tamoxifen or other medication longer than five years.


WNYT Staff

Copyright 2017 - WNYT-TV, LLC A Hubbard Broadcasting Company

Relay Media Amp
EXCLUSIVE: New health report recommends lowering PFOA and PFOS acceptable level

Glenville community members share concerns about proposed shooting range

Unfinished business frustrates state lawmakers as legislative session ends

In reversal, Trump orders halt to his family separation rule

Lawmakers: separating families is "not who we are"